Agenda IB
Elizabeth Bilsland
The current COVID-19 pandemic highlighted the vulnerability of our society to infections diseases. Whilst the current media focus is centered on SARS-CoV2, we must be prepared for the threat posed by drug-resistant parasites, fungi, and bacteria. The Synthetic Biology Laboratory (LaBS) was established in 2016 and is based on synthetic biology as a tool for drug discovery, using yeast and bacteria as hosts for heterologous expression and a platform for genome-wide screens. We have 3 well-established lines of investigation, which can further be improved and rapidly yield results.
Helena Coutinho Franco de Oliveira
We have focused on the role of plasma lipoprotein metabolism and associated proteins particularly relevant for the development of atherosclerosis, diabetes and obesity. Hormonal, nutritional and pharmacological regulation of key proteins involved in the metabolism of plasma lipoproteins are investigated with the goal of elucidating molecular mechanisms and putative therapeutic targets for cardio-metabolic disturbances.
Fernanda Ramos Gadelha
The research activities undertaken at our laboratory aim to study the Biochemistry of trypanosomatids, especially Trypanosoma cruzi, with emphasis on their bioenergetics and antioxidant mechanisms. We also test potential compounds to develop a more specific and less toxic therapy for Chagas disease.